TY - JOUR
T1 - Demographic characteristics of pediatric continuous renal replacement therapy
T2 - A report of the prospective pediatric continuous renal replacement therapy registry
AU - Symons, Jordan M.
AU - Chua, Annabelle N.
AU - Somers, Michael J.G.
AU - Baum, Michelle A.
AU - Bunchman, Timothy E.
AU - Benfield, Mark R.
AU - Brophy, Patrick D.
AU - Blowey, Douglas
AU - Fortenberry, James D.
AU - Chand, Deepa
AU - Flores, Francisco X.
AU - Hackbarth, Richard
AU - Alexander, Steven R.
AU - Mahan, John
AU - McBryde, Kevin D.
AU - Goldstein, Stuart L.
PY - 2007/7
Y1 - 2007/7
N2 - Background: This article reports demographic characteristics and intensive care unit survival for 344 patients from the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry, a voluntary multicenter observational network. Design, setting, participa nts, and measurements: Ages were newborn to 25 yr, 58% were male, and weights were 1.3 to 160 kg. Patients spent a median of 2 d in the intensive care unit before CRRT (range 0 to 135). At CRRT initiation, 48% received diuretics and 66% received vasoactive drugs. Mean blood flow was 97.9 ml/min (range 10 to 350 ml/min; median 100 ml/min); mean blood flow per body weight was 5 ml/min per kg (range 0.6 to 53.6 ml/min per kg; median 4.1 ml/min per kg). Days on CRRT were <1 to 83 (mean 9.1; median 6). A total of 56% of circuits had citrate anticoagulation, 37% had heparin, and 7% had no anticoagulation. Result s: Overall survival was 58%; survival differed across participating centers. Survival was lowest (51%) when CRRT was started for combined fluid overload and electrolyte imbalance. There was better survival in patients with principal diagnoses of drug intoxication (100%), renal disease (84%), tumor lysis syndrome (83%), and inborn errors of metabolism (73%); survival was lowest in liver disease/ transplant (31%), pulmonary disease/transplant (45%), and bone marrow transplant (45%). Overall survival was better for children who weighed >10 kg (63 versus 43%; P = 0.001) and for those who were older than 1 yr (62 versus 44%; P = 0.007). Conclusions: CRRT can be used successful ly for a wide range of critically ill children. Survival is best for those who have acute, specific abnormalilies and lack multiple organ involvement; sicker patients with selected diagnoses may have lower survival. Center differences might suggest opportunities to define best practices with future study.
AB - Background: This article reports demographic characteristics and intensive care unit survival for 344 patients from the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry, a voluntary multicenter observational network. Design, setting, participa nts, and measurements: Ages were newborn to 25 yr, 58% were male, and weights were 1.3 to 160 kg. Patients spent a median of 2 d in the intensive care unit before CRRT (range 0 to 135). At CRRT initiation, 48% received diuretics and 66% received vasoactive drugs. Mean blood flow was 97.9 ml/min (range 10 to 350 ml/min; median 100 ml/min); mean blood flow per body weight was 5 ml/min per kg (range 0.6 to 53.6 ml/min per kg; median 4.1 ml/min per kg). Days on CRRT were <1 to 83 (mean 9.1; median 6). A total of 56% of circuits had citrate anticoagulation, 37% had heparin, and 7% had no anticoagulation. Result s: Overall survival was 58%; survival differed across participating centers. Survival was lowest (51%) when CRRT was started for combined fluid overload and electrolyte imbalance. There was better survival in patients with principal diagnoses of drug intoxication (100%), renal disease (84%), tumor lysis syndrome (83%), and inborn errors of metabolism (73%); survival was lowest in liver disease/ transplant (31%), pulmonary disease/transplant (45%), and bone marrow transplant (45%). Overall survival was better for children who weighed >10 kg (63 versus 43%; P = 0.001) and for those who were older than 1 yr (62 versus 44%; P = 0.007). Conclusions: CRRT can be used successful ly for a wide range of critically ill children. Survival is best for those who have acute, specific abnormalilies and lack multiple organ involvement; sicker patients with selected diagnoses may have lower survival. Center differences might suggest opportunities to define best practices with future study.
UR - http://www.scopus.com/inward/record.url?scp=34548836853&partnerID=8YFLogxK
U2 - 10.2215/CJN.03200906
DO - 10.2215/CJN.03200906
M3 - Article
C2 - 17699489
AN - SCOPUS:34548836853
SN - 1555-9041
VL - 2
SP - 732
EP - 738
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 4
ER -